About Lung-MAP
The Lung-MAP trial is important in two ways. It uses genomic information to assign patients to an investigational therapy and it brings together key stakeholders – industry, academia, advocacy and government – to advance precision medicine research and development. Pfizer is proud to be part of this important collaboration, which has the potential to make a significant impact on the future of oncology drug development and, most important, lead to more effective treatment options for patients with lung cancer.
– Dr. Mace Rothenberg, Senior VP Clinical Development and Medical Affairs, CMO for Pfizer Oncology
Lung-MAP is a cancer clinical trial designed to quickly and efficiently test new treatments for advanced non-small cell lung cancers – which make up about 85 percent of all lung cancer diagnoses in the United States. Lung-MAP is offered at hospitals and clinics all over the country, making it easier for patients with lung cancer to participate and get access to investigational treatments to fight their cancer.
Lung-MAP is unique. It’s the first large-scale precision medicine trial in lung cancer supported by the National Cancer Institute (NCI), part of the federal National Institutes of Health, and is the first major NCI trial to test multiple treatments, simultaneously, under one “umbrella” design – which makes Lung-MAP more flexible and more efficient than typical cancer trials, and speeds the development process for new cancer drugs.
Lung-MAP is also an unprecedented public-private partnership, one that includes not only the NCI and the four adult cancer research groups in its National Clinical Trials Network, but also Friends of Cancer Research, the Foundation for the National Institutes of Health, Foundation Medicine, pharmaceutical companies, and several lung cancer advocacy organizations.
Here is how it works. Lung-MAP uses genomic profiling of a patient’s lung cancer to match them to a treatment being tested. Genomic profiling describes which genomic alterations known to drive the growth of cancer are present in a tumor. Patients who enroll in Lung-MAP can either use the results of genomic profiling they received as part of routine care or get on-study genomic profiling of their cancer. If there isn’t a genomic “match,” patients may have an option of participating in a study evaluating an immunotherapy-based treatment for lung cancer.
Launched in 2014 with a focus on squamous cell lung cancers, the trial expanded to include all histologic types of non-small cell lung cancers in 2019 and has registered more than 5,000 patients. Lung-MAP gives broad access throughout the United States to investigational treatments for lung cancer.
In 2024, genomic testing options for the trial were broadened significantly, meaning most patients can now be matched to Lung-MAP investigational treatments based on results of their past genomic testing, without needing to submit new tumor or blood samples.
The Lung-MAP trial is important in two ways. It uses genomic information to assign patients to an investigational therapy and it brings together key stakeholders – industry, academia, advocacy and government – to advance precision medicine research and development. Pfizer is proud to be part of this important collaboration, which has the potential to make a significant impact on the future of oncology drug development and, most important, lead to more effective treatment options for patients with lung cancer.
– Dr. Mace Rothenberg, Senior VP Clinical Development and Medical Affairs, CMO for Pfizer Oncology